AstraZeneca, in conjunction with KDIGO, invites you to an insider’s view of the “2020 KDIGO Guidelines for Diabetes in CKD” and a robust panel discussion challenging clinical inertia and calling a time for change in clinical practice for patients with Diabetes and CKD.
This webinar will be led by Professors Christoph Wanner (Nephrologist) and Sophia Zoungas (Endocrinologist) both members of the 2020 KDIGO Guidelines for Diabetes in CKD Guidelines working group. Additionally, Professor Zoungas, as Chair of the Living evidence for diabetes steering committee in Australia, will put the Living Guidelines for Diabetes into context and discuss implementation into local Clinical Practice.
Chairperson/Speaker
Professor Sophia Zoungas, MBBS, FRACP, PhD, is the head of Monash University’s School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia, and also leads the School’s Metabolism, Ageing and Genomics Division. She is an endocrinologist with clinical appointments at both Alfred Health and Monash Health, Melbourne, Victoria, Australia. Sophia is a Chair of the Living Evidence for Diabetes Steering Committee and a member of the writing group for the “2020 KDIGO clinical practice guideline for management of diabetes and CKD”.
Professor Christoph Wanner, MD, is professor of medicine and head of the Division of Nephrology at the University Hospital of Würzburg, Würzburg, Germany. Professor Wanner is recognized for his contributions to the field of cardiovascular disease, lipid disorders, and statin treatment in haemodialysis patients with diabetes.
He is a member of the writing group for the “2020 KDIGO clinical practice guideline for management of diabetes and CKD”
Agenda:
| TIME | TOPIC | CHAIRPERSON / SPEAKER |
|---|---|---|
| 7:30 pm - 7:35 pm | Welcome & Introduction | Professor Sophia Zoungas |
| 7:35 pm - 8:00 pm | An Insider’s view into “KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease” | Professor Christoph Wanner |
| 8:00 pm - 8:10 pm | Putting the “Living Evidence Guidelines for Diabetes” in context | Professor Sophia Zoungas |
| 8:10 pm - 8:30 pm | Panel Discussion: Is it time for a change in clinical practice? | Professors Zoungas & Wanner |
| 8:30 pm | Wrap Up & Close | Professor Sophia Zoungas |
-
Mexico Time: 4:30 AM (GMT -5)
Dubai Time: 1:30 PM (GMT +4)
Singapore Time: 5:30 PM (GMT +8)
This webinar is intended for HealthCare Professionals for medical educational purposes only. The webinar has been initiated, organized and funded by AstraZeneca
This webcast has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support.
PRIVACY STATEMENT: Your personal information (“Information”) will be collected and used by AstraZeneca Pty Ltd (“AstraZeneca”) for the purpose of administration of this webcast, for follow-up purposes and for any other purpose described in AstraZeneca’s Privacy Policy (see below for link). AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our Privacy Policy (https://www.astrazeneca.com.au/privacy-policy.html) for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint. AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com or email Medical Information enquiries to medinfo.australia@astrazeneca.com. AU-10781. E-011589. May 2021
